FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2038397855> ?p ?o ?g. }

• W2038397855 endingPage "7" @default.
• W2038397855 startingPage "3" @default.
• W2038397855 abstract "Cutaneous T-cell lymphoma (CTCL) is the general term used to describe extracutaneous non-Hodgkin’s lymphomas characterized by monoclonal expansion of skin-homing malignant T cells that can further be defined by the use of immunophenotypic markers and the presence of specific rearrangements of the T-cell receptor. The most frequently diagnosed form of CTCL is mycosis fungoides (MF) and its leukemic variant, Sezary syndrome (SS). MF most often presents as chronic eczematous or psoriasiform patches or plaques and can remain stable for many years. In some patients, MF progresses to involve lymph nodes, peripheral blood, bone marrow, and visceral organs. SS may present de novo with persistent exfoliative erythroderma accompanied by staphylococcal colonization, perivascular atypical lymphocytes in the dermis, and ‡1000 atypical T lymphocytes/mm in the blood, a criterion recently defined as a B2 blood rating by the International Society for Cutaneous Lymphomas. Extracorporeal photopheresis (ECP) combines blood apheresis with ultraviolet-A irradiation of psoralen-photosensitized peripheral blood mononuclear cells. ECP was first introduced in 1987 for the treatment of erythrodermic MF and SS. ECP was the first therapy to receive FDA approval for the treatment of CTCL based on a multicenter trial. Twenty-seven of 37 patients (76%) achieved a 25%–100% reduction in their erythroderma skin score. The Yale–New Haven Hospital experience has been reviewed by Heald et al. who treated 32 patients with ECP. Of 19 erythrodermic patients who were treated with ECP as their first therapy at Yale, five had greater than 75% improvement of their skin score, ten had 25%– 50% improvement, and four had less than 25% improvement. The majority of patients had improved quality of life. Heald et al. also evaluated long-term followup in 29 original CTCL patients in the original multicenter study. Their mean survival from the time of diagnosis was 60.3 months and from beginning of therapy it was 47.9 months, which exceeds their expected mean overall survival of 24–30 months reported in the literature. Four of six patients in the original study had prolonged responses. Favorable prognostic factors in both analyses were normal CD4-to-CD8 ratios at baseline suggesting that the presence of CD8+ cytotoxic T cells is required for response. Other studies conducted by investigators around the world have verified the initial study, reporting response rates between 50% and 75%, with complete response rates of 10%–5% (Table I). In patients with stable disease, investigators have claimed that photopheresis improves overall patient survival, improves quality of life, and extends response to total body skin electron beam radiation. This is in contrast to chemotherapy that does not increase overall survival if used as front-line therapy for CTCL patients. Although approved for treatment of erythrodermic patients (T4 skin rating), ECP has also produced remissions in patients with clinically early MF and with tumor phase disease. The addition of biological response modifiers, such as interferon a, granulocyte macrophage colony stimulating factor (GM-CSF), and retinoids, to ECP has been shown to result in higher response rates as reviewed by Rook et al. Gottlieb et al. reported a ten-year experience at the University of Pennsylvania using ECP alone and in combination with rIFN-a. Thirty-one of the 41 patients with CTCL who received more than six months of photopheresis therapy had evaluable disease. Twentyeight of the 31 patients had ECP monotherapy, with the following results: 7 of 28 patients had complete remission (25%), 13 of 28 patients had partial remissions (46%), and 8 out of 28 were nonresponders (29%). Seventy-one percent of the patients had greater than 50% clearing. This study found an overall intent-to-treat response rate of 48%, with 17% complete responses and 31% partial responses. A favorable response predictor was the presence of Sezary cells in the peripheral blood at onset of therapy. The median time to treatment failure was 18 months. The median survival from initiation of therapy was 77 months. The median survival from diagnosis was greater than 100 months and 77 months from initiation of ECP, suggesting that photopheresis increased overall survival in advanced patients." @default.
• W2038397855 created "2016-06-24" @default.
• W2038397855 creator A5030460763 @default.
• W2038397855 creator A5040949950 @default.
• W2038397855 creator A5053814686 @default.
• W2038397855 date "2003-09-01" @default.
• W2038397855 modified "2023-09-30" @default.
• W2038397855 title "Extracorporeal Photopheresis for the Treatment of Cutaneous T-Cell Lymphoma" @default.
• W2038397855 cites W1530351730 @default.
• W2038397855 cites W158917702 @default.
• W2038397855 cites W1976231672 @default.
• W2038397855 cites W1980469090 @default.
• W2038397855 cites W1985750819 @default.
• W2038397855 cites W1985907234 @default.
• W2038397855 cites W1996869817 @default.
• W2038397855 cites W1999812835 @default.
• W2038397855 cites W2000791674 @default.
• W2038397855 cites W2008459543 @default.
• W2038397855 cites W2020904611 @default.
• W2038397855 cites W2027255405 @default.
• W2038397855 cites W2044158364 @default.
• W2038397855 cites W2053897064 @default.
• W2038397855 cites W2059957759 @default.
• W2038397855 cites W2069834122 @default.
• W2038397855 cites W2072936571 @default.
• W2038397855 cites W2078842009 @default.
• W2038397855 cites W2088303434 @default.
• W2038397855 cites W2093163019 @default.
• W2038397855 cites W2103967014 @default.
• W2038397855 cites W2117944841 @default.
• W2038397855 cites W2118304583 @default.
• W2038397855 cites W2132433271 @default.
• W2038397855 cites W2147180662 @default.
• W2038397855 cites W2150604820 @default.
• W2038397855 cites W2153586393 @default.
• W2038397855 cites W2156741473 @default.
• W2038397855 cites W2337557724 @default.
• W2038397855 cites W2415166681 @default.
• W2038397855 cites W2430449321 @default.
• W2038397855 cites W2914122069 @default.
• W2038397855 cites W62038912 @default.
• W2038397855 cites W2523667715 @default.
• W2038397855 doi "https://doi.org/10.1007/s10227-003-5001-1" @default.
• W2038397855 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12958700" @default.
• W2038397855 hasPublicationYear "2003" @default.
• W2038397855 type Work @default.
• W2038397855 sameAs 2038397855 @default.
• W2038397855 citedByCount "26" @default.
• W2038397855 countsByYear W20383978552012 @default.
• W2038397855 countsByYear W20383978552013 @default.
• W2038397855 countsByYear W20383978552014 @default.
• W2038397855 countsByYear W20383978552015 @default.
• W2038397855 countsByYear W20383978552017 @default.
• W2038397855 countsByYear W20383978552018 @default.
• W2038397855 countsByYear W20383978552019 @default.
• W2038397855 countsByYear W20383978552020 @default.
• W2038397855 countsByYear W20383978552021 @default.
• W2038397855 countsByYear W20383978552022 @default.
• W2038397855 crossrefType "journal-article" @default.
• W2038397855 hasAuthorship W2038397855A5030460763 @default.
• W2038397855 hasAuthorship W2038397855A5040949950 @default.
• W2038397855 hasAuthorship W2038397855A5053814686 @default.
• W2038397855 hasConcept C141071460 @default.
• W2038397855 hasConcept C16005928 @default.
• W2038397855 hasConcept C203014093 @default.
• W2038397855 hasConcept C2776780870 @default.
• W2038397855 hasConcept C2777756187 @default.
• W2038397855 hasConcept C2779338263 @default.
• W2038397855 hasConcept C2779972918 @default.
• W2038397855 hasConcept C2781468836 @default.
• W2038397855 hasConcept C2909962264 @default.
• W2038397855 hasConcept C2911091166 @default.
• W2038397855 hasConcept C71924100 @default.
• W2038397855 hasConceptScore W2038397855C141071460 @default.
• W2038397855 hasConceptScore W2038397855C16005928 @default.
• W2038397855 hasConceptScore W2038397855C203014093 @default.
• W2038397855 hasConceptScore W2038397855C2776780870 @default.
• W2038397855 hasConceptScore W2038397855C2777756187 @default.
• W2038397855 hasConceptScore W2038397855C2779338263 @default.
• W2038397855 hasConceptScore W2038397855C2779972918 @default.
• W2038397855 hasConceptScore W2038397855C2781468836 @default.
• W2038397855 hasConceptScore W2038397855C2909962264 @default.
• W2038397855 hasConceptScore W2038397855C2911091166 @default.
• W2038397855 hasConceptScore W2038397855C71924100 @default.
• W2038397855 hasIssue "0" @default.
• W2038397855 hasLocation W20383978551 @default.
• W2038397855 hasLocation W20383978552 @default.
• W2038397855 hasOpenAccess W2038397855 @default.
• W2038397855 hasPrimaryLocation W20383978551 @default.
• W2038397855 hasRelatedWork W1813742668 @default.
• W2038397855 hasRelatedWork W1980366424 @default.
• W2038397855 hasRelatedWork W1985006851 @default.
• W2038397855 hasRelatedWork W2043680776 @default.
• W2038397855 hasRelatedWork W2044158364 @default.
• W2038397855 hasRelatedWork W2199352814 @default.
• W2038397855 hasRelatedWork W2318889189 @default.
• W2038397855 hasRelatedWork W2327768469 @default.
• W2038397855 hasRelatedWork W2366180244 @default.

• next